Login / Signup

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor.

Chunlin ChenWenwen ZhangMuhammad BariCristina AlmansaMike BarattaMaria Rosario
Published in: Clinical pharmacology : advances and applications (2021)
These results indicate that TAK‑906 is relatively insensitive to inhibition of cytochrome P450 3A4, and cardiovascular safety concerns associated with domperidone are unlikely to be elicited by trazpiroben under similar conditions.
Keyphrases
  • uric acid
  • anti inflammatory
  • metabolic syndrome